Need Help?

Search our site

LDN Research

. .

Posted Multiple Sclerosis, Safety and Tolerability

Institute of Experimental Neurology (INSPE) and Department of Neurology, San Raffaele Scientific Institute, Via Olgettina 58, Milan, Italy.

The really big surprise is a paper out of Milan Italy looking at 40 patients with PPMS. The researcher was Dr. Maira Gironi and colleagues at San Raffaelle Scientific Institute. This study progressed over 6 months - the longest of the three studies. The researchers aim was to study beta-endorphin levels (feel-good hormones) in patients treated with LDN along with an evaluation of the safety and tolerability of LDN. The secondary aim of the study was to look at the effect that LDN had on spasticity, pain, fatigue and quality of life. The trial clearly showed that LDN is safe and well-tolerated. However, the researchers noted that "only one patient had evidence of progression of neurologic disability.
This Italian study found statistically significant reduction in spasticity and an improvement in fatigue, depression and quality of life as measured at the end of the trial. The levels of beta-endorphin increased during the trial and paralleled clinical improvement. This gave researchers evidence of biologic activity by LDN. This study was published in The Multiple Sclerosis Journal. (no specifics given on jounal date or volume, but it would be fairly recent)

For more information on this study
Researchers: Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G.


Dr. Burt Berkson, M.D., Ph.D.

. .

Posted under Cancer | and Efficacy |

Burt Berkson, M.D., Ph.D., has gotten amazing results in his medical practice treating various conditions (including cancer, MS, and terminal liver disease) with Alpha Lipoic Acid and/or Low Dose Naltrexone. The site below features a transcript of an interview with Dr. Berkson in which he discusses some of his most notable cases:

http://tinyurl.com/berkson-on-ala-and-ldn
The site also reveals how incredibly difficult it has been for him to interest mainstream medicine in his discoveries.

A revealing video of Dr. Berkson in 2009 at the LDN Conference at the National Institutes of Health can be found here.

Dr. Berkson video.

UCSF Study

. .

Posted under LDN study to eliminate "placebo-effect" and evaluate Quality of Life. |

This is the UCSF study which we have all heard about. This was a randomized, double-masked, placebo-controlled, double cross-over 8-week trial. So, the scientific method used here was about as strict as one can get to eliminate bias and "placebo-effect". The study looked at Quality of life issues. They found that QOL for pain and mental health were improved in the 4 weeks that each participant was on LDN. They found that during this very short time "physical functioning" QOL improvements were NOT observed. The main adverse effect was vivid dreaming. LDN was well tolerated. A peer-reviewed paper giving full details of the study is pending publication.

Heading Level Three

This is another example of a paragraph followed by an unordered list. In posuere eleifend odio. Quisque semper augue mattis wisi. Maecenas ligula. Pellentesque viverra vulputate enim. Aliquam erat volutpat lorem ipsum dolorem.

An ordered list example:

  1. List item number one
  2. List item number two
  3. List item number thre

MindBrain Consortium, Summa Hospitals and Case-Western-Reserve Universtiy

. .

Posted under LDN readjustment dynamics |

This was run by Dr. David Pincus and the article I have gave no specifics on their study. It only said that the findings showed no significant findings - postive or negative. The authors did NOT conclude that LDN is not effective in MS patients. Their summary stated that findings by other researchers are compelling and that more research is required. They felt that allowing patients into their trial who were on auotimuune inhibitors (not specified) may have blunted the effect of the LDN readjustment dynamics on the immune system. They also recommended that patients be grouped by severity of symptoms in future studies.